Clinical effect of transcatheter arterial chemoembolization combined with local thermal ablation in treatment of large hepatocellular carcinoma and related influencing factors

Xing AiLi; Zheng JiaSheng

doi:10.3969/j.issn.1001-5256.2019.01.018

Volume 35 Issue 1

Jan. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(1): 98-103

PDF( 1985 KB)

Clinical effect of transcatheter arterial chemoembolization combined with local thermal ablation in treatment of large hepatocellular carcinoma and related influencing factors

DOI: 10.3969/j.issn.1001-5256.2019.01.018

Minimally Invasive Interventional Center of Oncology, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Research funding:

Published Date: 2019-01-20

Abstract

Abstract

Objective To investigate the clinical effect of transcatheter arterial chemoembolization (TACE) combined with local thermal ablation in the treatment of large hepatocellular carcinoma (HCC) .Methods A retrospective analysis was performed for the clinical data of134 patients with large HCC who underwent TACE combined with local thermal ablation in our center from January 2010 to September 2016.In all patients, 75 underwent TACE combined with microwave ablation and 59 underwent TACE combined with radiofrequency ablation.The effect of ablation (complete ablation and partial ablation) was evaluated, and follow-up was performed to observe the recurrence of intrahepatic tumor in patients with complete ablation.The chi-square test and logistic regression analysis were used to evaluate the influencing factors for the effect of ablation, and the Kaplan-Meier survival analysis and the Cox proportional hazards model were used to analyze recurrence-free survival and related influencing factors.Results Of all patients, 88 achieved complete ablation and 46 patients achieved partial ablation, resulting in a complete ablation rate of 65.7%.The logistic regression analysis showed that presence of portal vein tumor thrombus (odds ratio[OR]=5.051, P=0.017) , incomplete tumor capsule (OR=4.199, P=0.007) , and dangerous location of tumor (OR=4.967, P=0.001) were independent risk factors for the effect of ablation.The patients with complete ablation had a median recurrencefree survival of 17.41±2.73 months and the 1-, 3-, and 5-year recurrence-free survival rates were 61.4%, 23.3%, and 17.7%, respectively;the multivariate analysis showed that multiple tumors (OR=1.708, P=0.041) was an independent risk factor.There were no significant differences between TACE combined with microwave ablation and TACE combined with radiofrequency ablation in the effect of ablation (χ2=2.431, P=0.119) and tumor recurrence (χ2=3.292, P=0.070) .ConclusionPresence of portal vein tumor thrombus, tumor capsule integrity, and tumor location are important influencing factors for the effect of ablation in patients with large HCC.For patients with complete ablation, the number of tumors can be used to assess the risk of intrahepatic tumor recurrence.
- carcinoma, hepatocellular,
- chemoembolization, therapeutic,
- catheter ablation,
- treatment outcome,
- risk factors

FullText(HTML)

References(24)

References

[1]FORNER A, REIG M, BRUIX J.Hepatocellular carcinoma[J].The Lancet, 2018, 391 (10127) :1301-1314.

[2]BALOGH J, VICTOR DR, ASHAM EH, et al.Hepatocellular carcinoma:A review[J].J Hepatocell Carcinoma, 2016, 3:41-53.

[3]GUIMARAES M, UFLACKER R.Locoregional therapy for hepatocellular carcinoma[J].Clin Liver Dis, 2011, 15 (2) :395-421.

[4]SHI J, SUN Q, WANG Y, et al.Comparison of microwave ablation and surgical resection for treatment of hepatocellular carcinomas conforming to Milan criteria[J].J Gastroenterol Hepatol, 2014, 29 (7) :1500-1507.

[5]HOCQUELET A, BALAGEAS P, LAURENT C, et al.Radiofrequency ablation versus surgical resection for hepatocellular carcinoma within the Milan criteria:A study of 281 Western patients[J].Int J Hyperthermia, 2015, 31 (7) :749-757.

[6]LEE DH, LEE JM, LEE JY, et al.Radiofrequency ablation of hepatocellular carcinoma as first-line treatment:Long-term results and prognostic factors in 162 patients with cirrhosis[J].Radiology, 2014, 270 (3) :900-909.

[7]GUO XD, SUN SS, LI WD, et al.Effects of transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation on patients with intermediate stage primary liver cancer[J/CD].Chin J Liver Dis:Electronic Edition, 2018, 10 (2) :30-36. (in Chinese) 郭晓笛, 孙莎莎, 李文东, 等.肝动脉化疗栓塞术联合射频消融术治疗中期原发性肝癌患者的疗效[J/CD].中国肝脏病杂志:电子版, 2018, 10 (2) :30-36.

[8]XU Y, SHEN Q, WANG N, et al.Percutaneous microwave ablation of 5-6 cm unresectable hepatocellular carcinoma:Local efficacy and long-term outcomes[J].Int J Hyperthermia, 2016.[Epub ahead of print]

[9]YIN XY, XIE XY, LU MD, et al.Percutaneous thermal ablation of medium and large hepatocellular carcinoma:Long-term outcome and prognostic factors[J].Cancer, 2009, 115 (9) :1914-1923.

[10]ZHAI B.Strategy and prospect of thermal ablation for treatment of large hepatocellular carcinoma[J/CD].Eletronic JLiver Tumor, 2017, 4 (4) :13-16. (in Chinese) 翟博.大肝癌热消融治疗策略及展望[J/CD].肝癌电子杂志, 2017, 4 (4) :13-16.

[11]CHEN WY, REN N.Advances in molecular targeted therapy for hepatocellular carcinoma[J].J Clin Hepatol, 2018, 34 (7) :1387-1394. (in Chinese) 陈万勇, 任宁.肝细胞癌分子靶向治疗进展[J].临床肝胆病杂志, 2018, 34 (7) :1387-1394.

[12]TAKAKI H, YAMAKADO K, URAKI J, et al.Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm[J].J Vasc Interv Radiol, 2009, 20 (2) :217-224.

[13]LIM C, MISE Y, SAKAMOTO Y, et al.Above 5 cm, size does not matter anymore in patients with hepatocellular carcinoma[J].World J Surg, 2014, 38 (11) :2910-2918.

[14]DELIS SG, BAKOYIANNIS A, TASSOPOULOS N, et al.Hepatic resection for hepatocellular carcinoma exceeding Milan criteria[J].Surg Oncol, 2010, 19 (4) :200-207.

[15]CHANG YJ, CHUNG KP, CHANG YJ, et al.Long-term survival of patients undergoing liver resection for very large hepatocellular carcinomas[J].Br J Surg, 2016, 103 (11) :1513-1520.

[16]ZHANG W, TAN Y, JIANG L, et al.Liver resection associated with better outcomes for single large hepatocellular carcinoma located in the same section[J].Medicine (Baltimore) , 2017, 96 (10) :e6246.

[17]SONG SH, GUO J, ZOU C.Factors influencing postoperative recurrence in patients with primary liver cancer after hepatectomy[J].J Pract Hepatol, 2017, 20 (2) :203-206. (in Chinese) 宋书红, 郭俊, 邹灿.肝癌手术切除术后复发相关因素分析[J].实用肝脏病杂志, 2017, 20 (2) :203-206.

[18]IEZZI R, POMPILI M, LA TORRE MF, et al.Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma[J].Dig Liver Dis, 2015, 47 (3) :242-248.

[19]SHI M, ZHANG CQ, ZHANG YQ, et al.Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin[J].World J Surg, 2004, 28 (4) :376-381.

[20]REN ZG.Immunotherapy for hepatocellular carcinoma[J].JClin Hepatol, 2018, 34 (7) :1371-1373. (in Chinese) 任正刚.肝细胞癌的免疫治疗[J].临床肝胆病杂志, 2018, 34 (7) :1371-1373.

[21]XU LF, SUN HL, CHEN YT, et al.Large primary hepatocellular carcinoma:Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy[J].J Gastroenterol Hepatol, 2013, 28 (3) :456-463.

[22]BIOLATO M, MARRONE G, RACCO S, et al.Transarterial chemoembolization (TACE) for unresectable HCC:A new life begins?[J].Eur Rev Med Pharmacol Sci, 2010, 14 (4) :356-362.

[23]TANG C, SHEN J, FENG W, et al.Combination therapy of radiofrequency ablation and transarterial chemoembolization for unresectable hepatocellular carcinoma:A retrospective study[J].Medicine (Baltimore) , 2016, 95 (20) :e3754.

[24]CHANG P, ZHANG HY, XIAO M.Efficacy of transcatheter arterial chemoembolization alone or combined with microwave ablation in treatment of primary large liver cancer:A comparetive analysis[J].J Clin Hepatol, 2015, 31 (6) :880-885. (in Chinese) 常鹏, 张洪义, 肖梅.单纯经肝动脉化疗栓塞术及其联合微波消融治疗原发性大肝癌的疗效对比分析[J].临床肝胆病杂志, 2015, 31 (6) :880-885.

Relative Articles

[1]	Jie LU, Dingchun LI, Ye LIU, Linna YUAN, Zhiwen DUAN, Wu LI. Clinical efficacy of low-dose plasma exchange combined with double plasma molecular absorption system/hemoperfusion in treatment of acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(11): 2526-2531. doi: 10.3969/j.issn.1001-5256.2022.11.017
[2]	Wu YiChen, Yao HongYu, Wang KaiLi, Jiang QiYu, Liu Chang, Xing HanQian, Liu SuXia, You ShaoLi, Zhao Jun. Effect of plasma exchange on bioactivity of peripheral blood CD34+ cells in patients with acute-on-chronic (subacute) liver failure[J]. Journal of Clinical Hepatology, 2018, 34(11): 2383-2387. doi: 10.3969/j.issn.1001-5256.2018.11.023
[3]	Li Shuang, Chen Yu. Coping with shortage of plasma-The new therapeutic pattern of non-bioartificial liver[J]. Journal of Clinical Hepatology, 2017, 33(9): 1687-1692. doi: 10.3969/j.issn.1001-5256.2017.09.012
[4]	Hou HuanRong, Shang Jia, Kang Yi, Li YuKui, Ceng YanLi, Ding GangQiang, Mao ZhongShan, Xiao ErHui. Clinical effect of plasma exchange combined with hemofiltration in patients with subacute liver failure induced by antitubercular agents[J]. Journal of Clinical Hepatology, 2016, 32(2): 342-346. doi: 10.3969/j.issn.1001-5256.2016.02.030
[5]	Wang QingHai, Tian Yi. Clinical efficacy of modulation of intestinal microecology and plasmapheresis for preventing and treating multiple organ failure in patients with severe hepatitis[J]. Journal of Clinical Hepatology, 2015, 31(9): 1426-1429. doi: 10.3969/j.issn.1001-5256.2015.09.015
[6]	Yu BingXue, Wu JianLin, Wu JiZhou, Wang ZunFu. Effect of non-bioartificial liver support system on serum manganese levels in patients with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2015, 31(8): 1311-1313. doi: 10.3969/j.issn.1001-5256.2015.08.031
[7]	Zhang LiangJie, Chen HuiJuan, Zhao ShouSong. Effects of artificial liver plasma exchange on cytokines in patients with liver failure[J]. Journal of Clinical Hepatology, 2015, 31(4): 578-581. doi: 10.3969/j.issn.1001-5256.2015.04.024
[8]	Wang Xian, Wang ShaoYang, Huang DeDong, Chen Jian, Chen DeLiang. Analysis of short-term prognostic factors in patients with HBV-related acute-on-chronic liver failure treated with artificial liver support system[J]. Journal of Clinical Hepatology, 2014, 30(4): 367-369. doi: 10.3969/j.issn.1001-5256.2014.04.020
[9]	Wu ShaoHong, Gan JianHe, Huang XiaoPing, Lin Hua, Lu NianFang, Wu JiangQuan, Zheng RuiQiang. Clinical effect of albumin dialysis combined with plasma perfusion in treatment of liver failure[J]. Journal of Clinical Hepatology, 2014, 30(5): 434-437. doi: 10.3969/j.issn.1001-5256.2014.05.013
[10]	Zhang Lin, Zhao ShouSong. Clinical efficacy of plasma exchange therapy in treatment of liver failure[J]. Journal of Clinical Hepatology, 2014, 30(10): 1015-1019. doi: 10.3969/j.issn.1001-5256.2014.10.010
[11]	Hu QiJiang, Jiang YingAn. Evaluation of the therapeutic efficacy of lamivudine combined with plasma exchange for treating acute-on-chronic hepatitis B liver failure [J]. Journal of Clinical Hepatology, 2013, 29(2): 107-109.
[12]	Zhou Jian, Wan Hong. Relationship between changes in serum cytokine levels after artificial liver therapy and clinical prognosis in patients with liver failure[J]. Journal of Clinical Hepatology, 2013, 29(7): 535-537. doi: 1001-5256 (2013) 07-0535-03
[13]	Zhang AiMin, You ShaoLi, Wan ZhiHong, Rong YiHui, Zhu Bing, Zang Hong, Xin ShaoJie. Combination therapy of plasma perfusion, plasma exchange, and entecavir in patients with hepatitis B acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2012, 28(10): 744-747.
[14]	Liao JinMao, Li ZhuoRi, Hu XiaoXuan. The therapeutic effect of plasma exchange therapy in patients with severe hepatitis[J]. Journal of Clinical Hepatology, 2012, 28(4): 302-304.
[15]	Zhang WenHua, Jia WenLing, Zhou ZiYing, Tang HaiTao, Wang FengMei. Investigation on the method and safety of the non-heparinized plasma exchange therapy in treating patients with hepatic failure[J]. Journal of Clinical Hepatology, 2012, 28(1): 50-52.
[18]	Gao QingWei, Hu MeiTing, Yuan DeSheng, Wang Yong, Li BenKe, Han Guang, Wang RuGang, Sun WeiXiang. Analysis of influence factor and efficacy of plasma exchange therapy for chronic severe hepatitis B[J]. Journal of Clinical Hepatology, 2007, 23(5): 349-351.

Supplements(0)

Cited By

Cited by

Periodical cited type(30)

1.	邹暾，龙文兴，周定中，周忠威，彭俊. 原发性肝癌采用肝动脉化疗栓塞术联合RFA的疗效及对血清miR-202、FHIT和P16蛋白水平的影响. 湘南学院学报(医学版). 2024(01): 27-29+78 .
2.	余令兵. TACE中灌注吡柔比星治疗原发性肝癌的临床疗效及对免疫功能、血清肿瘤标志物水平的影响. 中国卫生工程学. 2024(02): 238-240+243 .
3.	王娟，田宁，刘超，张山燕，周远. 肝动脉化疗栓塞联合靶向药物及免疫检查点抑制剂治疗中晚期肝癌的效果及对患者生存时间的影响. 大医生. 2024(07): 36-39 .
4.	胡迎超. 血清甲胎蛋白和巨噬细胞移动抑制因子水平与原发性肝癌肝动脉化疗栓塞术患者预后的关系. 慢性病学杂志. 2023(01): 116-118 .
5.	周菲菲，黄荣，蒋军，毛晓帆. 平均血小板体积/淋巴细胞比值对原发性肝癌SBRT治疗预后的评估价值. 西部医学. 2023(04): 563-567 .
6.	何翠瑛，苏贞栋，陈燕红，周林荣，杨宇，姚清深. 阿帕替尼联合TACE治疗原发性肝癌复发生存的影响因素分析. 中西医结合肝病杂志. 2023(04): 298-302 .
7.	张栋华，宋爱军，胡海军，刘朝阳. 经导管动脉化疗栓塞联合射频消融术治疗原发性肝癌患者的临床疗效. 癌症进展. 2023(08): 858-861 .
8.	王如芹，高振东，高宗毅. 影响立体定向放射治疗原发性肝癌效果的相关因素分析. 中国基层医药. 2022(02): 285-290 .
9.	刘爽. 基于聚焦解决模式的放松训练干预在肝癌射频消融术围术期护理中的应用效果评估. 黑龙江医学. 2022(01): 76-78 .
10.	兰海涛，黄真婷，王小星. 超选择性肝动脉化疗栓塞术联合阿帕替尼对中晚期原发性肝癌患者血清MMP表达的影响. 数理医药学杂志. 2022(04): 597-599 .
11.	张雪婷，周祖邦，薛亚娥，张明华，杜学晴. TACE联合热消融与单独TACE治疗结直肠癌肝转移疗效：Meta分析. 中国介入影像与治疗学. 2022(05): 278-283 .
12.	杜炜玮，段铮，胡斌. 经皮RFA治疗原发性肝癌的效果及对血清TGF-β1、EGR2水平的影响. 分子诊断与治疗杂志. 2022(04): 635-638 .
13.	武文华，冯秦辉，蔡芝芳，贾晓黎，杨锐华，党双锁. 经导管动脉化疗栓塞术联合超声引导射频消融术治疗原发性肝癌对疗效及免疫功能的影响. 中国医师进修杂志. 2022(05): 459-464 .
14.	王瑛，袁鹤立，赵利，张亚丽，马向明. 伴营养不良风险的原发性肝癌患者临床特征及预后因素分析. 中西医结合肝病杂志. 2022(06): 494-498 .
15.	柯映平，叶绍光，卢舜彬. 肝动脉化疗栓塞术联合FOLFOX方案持续性动脉灌注化疗在巴塞罗那B期原发性肝癌患者中的应用效果. 中国当代医药. 2022(18): 73-76 .
16.	张贻庆，崔贵医，杨磊，刘刚，冯世杰，王劲. 肝肿瘤切除术与射频消融术治疗原发性肝癌的疗效及其对血清AFP、CEA、CA125水平的影响. 实用癌症杂志. 2022(08): 1316-1319 .
17.	孙玉，张洪海，袁春旺，龙江，郑加生，张永宏. C反应蛋白/白蛋白比值影响肝动脉栓塞联合微波消融治疗中期肝细胞癌的预后. 肝胆胰外科杂志. 2022(10): 587-592 .
18.	郝晓光，李伟靖，朱丽娜，史博，艾宁，吴勇超，李智岗. 中晚期肝癌患者经导管化疗栓塞治疗后序贯射频消融手术治疗时机的选择. 介入放射学杂志. 2022(09): 908-912 .
19.	章甜，贾思静，孙冬雪，龙奉玺，唐东昕，杨柱. 拉米夫定联合TACE治疗HBV相关性中晚期肝癌的Meta分析. 临床医学研究与实践. 2021(13): 36-41+47 .
20.	付卫东，尚靖智. 肝动脉化疗栓塞术联合经皮射频消融术治疗中晚期肝癌的临床疗效评价. 吉林医学. 2021(05): 1095-1098 .
21.	谷涛，于经瀛. 肝动脉化疗栓塞术治疗原发性进展性肝细胞癌新进展. 协和医学杂志. 2021(03): 380-385 .
22.	刘人杰. 索拉菲尼治疗原发性肝癌的效果及对患者血清HSP90α、VEGF水平的影响. 中国医学创新. 2021(14): 15-19 .
23.	高磊磊，秦帅鑫，陈威，候振国. TACE联合RFA治疗中期原发性肝癌的疗效及对患者血清GP73、AFP和AFP-L3水平的影响. 临床和实验医学杂志. 2021(13): 1388-1391 .
24.	金文彪. 肝动脉化疗栓塞联合射频消融在原发性肝癌中的价值. 中国卫生标准管理. 2021(17): 48-51 .
25.	范隼，钟鹏，巫兆国. 经肝动脉化疗栓塞联合同步射频消融术治疗肝癌的初步临床研究. 吉林医学. 2021(10): 2389-2390 .
26.	曹昆昆，李晓伟，付志刚，翟健，曲增强，丁宁. 微波消融同步联合经导管动脉化疗栓塞治疗膈下肝细胞癌. 中国介入影像与治疗学. 2021(11): 659-662 .
27.	卢毅，周任. 肝动脉化疗栓塞联合射频消融治疗原发性小肝癌的临床效果及对患者免疫功能的影响. 广西医学. 2021(18): 2161-2165 .
28.	何勇. 肝动脉介入化疗栓塞术联合阿帕替尼在晚期肝癌中的应用. 临床医药实践. 2020(03): 181-183 .
29.	徐蓉，华忠. 肝硬化并发原发性肝癌的流行病学特征、危险因素及相关预防干预对策研究. 中西医结合肝病杂志. 2020(04): 357-359+366 .
30.	刘峥嵘，俞巍. 肝动脉化疗栓塞术和肝动脉栓塞术治疗肝细胞癌的疗效. 血管与腔内血管外科杂志. 2019(02): 139-143 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2029) PDF downloads(345)

Clinical effect of transcatheter arterial chemoembolization combined with local thermal ablation in treatment of large hepatocellular carcinoma and related influencing factors

DOI: 10.3969/j.issn.1001-5256.2019.01.018